辉瑞就是受重磅单品影响的典型案例。2022年该公司凭借新冠产品Comirnaty和Paxlovid一举登上全球药企总营收和制药业务收入两张冠军宝座。但随着疫情退去，新冠类产品临床需求萎缩严重，Comirnaty和Paxlovid销售额出现断崖式下跌，2023年辉瑞总营收几近腰斩(-41%)，跌至榜单第四名，制药业务虽然仍排在第一，但后劲不足...
2022年该公司凭借新冠产品Comirnaty和Paxlovid一举登上全球药企总营收和制药业务收入两张冠军宝座。 但随着疫情退去,新冠类产品临床需求萎缩严重,Comirnaty和Paxlovid销售额出现断崖式下跌,2023年辉瑞总营收几近腰斩(-41%),跌至榜单第四名,制药业务虽然仍排在第一,但后劲不足。为此,辉瑞斥430亿美元巨资将ADC龙头企...
As of June 3, 2022, there were 1,521 drugs and vaccines in development targeting the coronavirus disease (COVID-19).
中位 PFS 和中位 OS 分别为 5.7 个月和 10.2 个月,中位 DoR 为 7.9 个月。在删除 4 例因 COVID-19 死亡的病例信息后,T-DXd 用于 HER2 阳性晚期胃癌患者的中位 OS 达 12.4 个月。 图3. DG06 研究的 OS 结果 DG06 研究成果让中国 HER2 阳性晚期胃癌患者看到了更多选择,基于该研究结果,2024 年 8...
6月10日,美国 Pharmaceutical Executive《制药经理人》杂志公布了最新的全球制药企业50强排名。 COVID-19疫苗和疗法带来的“意外之财”以前所未有的方式改变了全球生物制药企业的排名,但随着即将到来的最痛苦的专利悬崖期和全球环境的挑战,这些改变可能会趋于平稳,我们更应该将一些焦点转移到可预期的非COVID方面的上升...
与2022年相比,上榜的药企名单并未发生变化,变化的只是排名顺序。在位居榜首近10年后,罗氏公司(Roche)终于从年度研发投入榜首的位置上跌落,默沙东(Merck & Co.)以超过300亿美元的巨额研发投入首次登上榜首。 2023年上充满变化和调整的一年,COVID-19从制药行业前沿逐渐消失,而新型减肥药GLP-1类受体激动剂走上舞台...
The federation said on its website that Kramer, a top contender for Olympic gold, tested positive again for COVID-19 following a first positive result over the weekend, and thus cannot compete in Beijing. "Our worst fears have become a sad reality," the federation said on Twitter. ...
Prospering in the pandemic: 50 top and 50 hardest hit companies. The Soaring and the Falling in 2020: How the COVID 19 pandemic has changed the business world and how some are able to do well in this time.
As of May 3, confirmed COVID-19 cases hit 3.4 million globally, with the death toll surpassing 243,000 and more than one million patients recovered, according to the statistics released by Johns Hopkins University. RELATED STORIES U.S. respiratory illnesses on the rise in ...
toll the human suffering is a disaster. but the economic cost to residents and the insurance industry will add to the woes facing southern california. tim smart jan. 10, 2025 trump defiant after criminal sentencing the judge’s ruling means that trump will not be fined, will not receive ...